BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

15555

539787

HCG

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

HEALTHCARE GLOB. ENT. LTD performance

Today’s low

Today’s high

₹ 542.90 ₹ 570.00
₹ 562.45

52 week low

52 week high

₹ 330.65 ₹ 601.95
₹ 562.45

Open Price

₹ 559.00

Prev. Close

₹ 546.70

Volume (Shares)

351748.00

Total traded value

₹ 1978.40

Upper Circuit

₹ 656.00

Lower Circuit

₹ 437.40

info

HEALTHCARE GLOB. ENT. LTD Share Price Update

As of the latest trading session, HEALTHCARE GLOB. ENT. LTD share price is currently at ₹ 562.45, which is up by ₹ 15.75 from its previous closing. Today, the stock has fluctuated between ₹ 542.90 and ₹ 570.00. Over the past year, HEALTHCARE GLOB. ENT. LTD has achieved a return of 50.27 %. In the last month alone, the return has been 3.28 %. Read More...

HEALTHCARE GLOB. ENT. LTD fundamentals


  • Market cap (Cr)

    7,834.34

  • P/E Ratio (TTM)

    -803.24

  • Beta

    0.57

  • Book Value / share

    87.61

  • Return on equity

    3.22%

  • EPS (TTM)

    2.26

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -37.33

info icon alternate text
  • Market cap (Cr)

    7,908.17

  • P/E Ratio (TTM)

    -803.24

  • Beta

    0.56

  • Book Value / share

    87.61

  • Return on equity

    3.22%

  • EPS (TTM)

    2.26

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -37.33

info icon alternate text

HEALTHCARE GLOB. ENT. LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 311.67
Operating Expense 319.35
Net Profit -37.33
Net Profit Margin (%) -11.97
Earnings Per Share (EPS) -2.68
EBITDA 12.78
Effective Tax Rate (%) -2.61
Particulars SEP 2024 (Values in Cr)
Revenue 328.45
Operating Expense 316.13
Net Profit 17.95
Net Profit Margin (%) 5.46
Earnings Per Share (EPS) 1.29
EBITDA 71.36
Effective Tax Rate (%) 21.64
Particulars JUN 2024 (Values in Cr)
Revenue 292.94
Operating Expense 288.90
Net Profit 11.72
Net Profit Margin (%) 4.00
Earnings Per Share (EPS) 0.84
EBITDA 60.39
Effective Tax Rate (%) 22.94
Particulars MAR 2024 (Values in Cr)
Revenue 279.27
Operating Expense 264.81
Net Profit -1.76
Net Profit Margin (%) -0.63
Earnings Per Share (EPS) -0.13
EBITDA 42.87
Effective Tax Rate (%) 149.02
Particulars DEC 2023 (Values in Cr)
Revenue 285.05
Operating Expense 275.56
Net Profit 8.67
Net Profit Margin (%) 3.04
Earnings Per Share (EPS) 0.62
EBITDA 53.79
Effective Tax Rate (%) 43.29
Particulars MAR 2024 (Values in Cr)
Revenue 1170.66
Operating Expense 1117.06
Net Profit 32.80
Net Profit Margin (%) 2.80
Earnings Per Share (EPS) 2.36
EBITDA 200.69
Effective Tax Rate (%) 38.91
Particulars MAR 2023 (Values in Cr)
Revenue 1005.57
Operating Expense 955.77
Net Profit 40.19
Net Profit Margin (%) 3.99
Earnings Per Share (EPS) 2.89
EBITDA 188.07
Effective Tax Rate (%) 30.24
Particulars MAR 2022 (Values in Cr)
Revenue 849.83
Operating Expense 834.12
Net Profit 38.25
Net Profit Margin (%) 4.50
Earnings Per Share (EPS) 2.95
EBITDA 212.20
Effective Tax Rate (%) 52.80
Particulars MAR 2021 (Values in Cr)
Revenue 608.86
Operating Expense 684.83
Net Profit -191.54
Net Profit Margin (%) -31.45
Earnings Per Share (EPS) -15.28
EBITDA -55.61
Effective Tax Rate (%) 6.58
Particulars MAR 2020 (Values in Cr)
Revenue 688.33
Operating Expense 735.00
Net Profit -53.30
Net Profit Margin (%) -7.74
Earnings Per Share (EPS) -6.02
EBITDA 96.94
Effective Tax Rate (%) 18.57
Particulars MAR 2024 (Values in Cr)
Book Value / Share 59.28
ROE % 3.14
ROCE % 7.19
Total Debt to Total Equity 1.29
EBITDA Margin 18.39
Particulars MAR 2023 (Values in Cr)
Book Value / Share 61.86
ROE % 1.35
ROCE % 6.56
Total Debt to Total Equity 1.05
EBITDA Margin 18.44
Particulars MAR 2022 (Values in Cr)
Book Value / Share 62.61
ROE % -0.62
ROCE % 4.62
Total Debt to Total Equity 1.21
EBITDA Margin 17.91
Particulars MAR 2021 (Values in Cr)
Book Value / Share 52.11
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.16
EBITDA Margin 14.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 42.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.34
EBITDA Margin 15.27
Particulars MAR 2024 (Values in Cr)
Book Value / Share 85.33
ROE % 3.22
ROCE % 6.23
Total Debt to Total Equity 0.47
EBITDA Margin 19.35
Particulars MAR 2023 (Values in Cr)
Book Value / Share 82.31
ROE % 3.07
ROCE % 5.85
Total Debt to Total Equity 0.31
EBITDA Margin 18.70
Particulars MAR 2022 (Values in Cr)
Book Value / Share 78.96
ROE % 1.19
ROCE % 4.55
Total Debt to Total Equity 0.41
EBITDA Margin 18.75
Particulars MAR 2021 (Values in Cr)
Book Value / Share 70.19
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.85
EBITDA Margin 16.02
Particulars MAR 2020 (Values in Cr)
Book Value / Share 69.29
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.99
EBITDA Margin 18.56
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 303.07
Total Assets 2707.49
Total Liabilities 2707.49
Total Equity 865.11
Share Outstanding 139289687
Price to Book Ratio 3.96
Return on Assets (%) 1.77
Return on Capital (%) 3.13
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 196.63
Total Assets 2316.01
Total Liabilities 2316.01
Total Equity 869.41
Share Outstanding 139116062
Price to Book Ratio 3.19
Return on Assets (%) 1.26
Return on Capital (%) 2.31
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 197.50
Total Assets 2219.52
Total Liabilities 2219.52
Total Equity 883.71
Share Outstanding 139011992
Price to Book Ratio 3.42
Return on Assets (%) 2.42
Return on Capital (%) 4.16
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.85
Total Assets 2035.61
Total Liabilities 2035.61
Total Equity 714.00
Share Outstanding 125359284
Price to Book Ratio 2.72
Return on Assets (%) -9.50
Return on Capital (%) -16.32
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 32.01
Total Assets 2253.17
Total Liabilities 2253.17
Total Equity 419.76
Share Outstanding 88690629
Price to Book Ratio 1.08
Return on Assets (%) -4.73
Return on Capital (%) -10.23
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 237.33
Total Assets 2187.89
Total Liabilities 2187.89
Total Equity 1188.58
Share Outstanding 139289687
Price to Book Ratio 3.96
Return on Assets (%) 1.55
Return on Capital (%) 2.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 80.36
Total Assets 1729.70
Total Liabilities 1729.70
Total Equity 1145.12
Share Outstanding 139116062
Price to Book Ratio 3.19
Return on Assets (%) 2.32
Return on Capital (%) 3.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 119.95
Total Assets 1643.61
Total Liabilities 1643.61
Total Equity 1097.69
Share Outstanding 139011992
Price to Book Ratio 3.42
Return on Assets (%) 2.32
Return on Capital (%) 3.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 14.46
Total Assets 1574.51
Total Liabilities 1574.51
Total Equity 923.78
Share Outstanding 125359284
Price to Book Ratio 2.72
Return on Assets (%) -12.16
Return on Capital (%) -16.47
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 15.13
Total Assets 1768.91
Total Liabilities 1768.91
Total Equity 614.50
Share Outstanding 88690629
Price to Book Ratio 1.08
Return on Assets (%) -3.01
Return on Capital (%) -5.16
Particulars MAR 2024 (Values in Cr)
Net Income 67.72
Cash from Operations 331.94
Cash from Investing -225.72
Cash from Financing -64.01
Net change in Cash -5.16
Free Cash Flow 517.62
Particulars MAR 2023 (Values in Cr)
Net Income 44.88
Cash from Operations 274.30
Cash from Investing -133.03
Cash from Financing -140.06
Net change in Cash -21.50
Free Cash Flow 407.54
Particulars MAR 2022 (Values in Cr)
Net Income 87.77
Cash from Operations 243.82
Cash from Investing 124.58
Cash from Financing -154.88
Net change in Cash 189.82
Free Cash Flow 315.05
Particulars MAR 2021 (Values in Cr)
Net Income -228.66
Cash from Operations 82.55
Cash from Investing -171.10
Cash from Financing 112.24
Net change in Cash 61.65
Free Cash Flow 117.97
Particulars MAR 2020 (Values in Cr)
Net Income -119.26
Cash from Operations 156.85
Cash from Investing -101.38
Cash from Financing -58.42
Net change in Cash -29.67
Free Cash Flow 264.66
Particulars MAR 2024 (Values in Cr)
Net Income 54.86
Cash from Operations 227.83
Cash from Investing -249.19
Cash from Financing 105.36
Net change in Cash 50.87
Free Cash Flow 352.64
Particulars MAR 2023 (Values in Cr)
Net Income 57.62
Cash from Operations 147.64
Cash from Investing -137.70
Cash from Financing -41.71
Net change in Cash -49.02
Free Cash Flow 249.76
Particulars MAR 2022 (Values in Cr)
Net Income 81.04
Cash from Operations 139.11
Cash from Investing 48.64
Cash from Financing -41.04
Net change in Cash 132.00
Free Cash Flow 181.56
Particulars MAR 2021 (Values in Cr)
Net Income -205.05
Cash from Operations 30.45
Cash from Investing -245.62
Cash from Financing 235.92
Net change in Cash 61.18
Free Cash Flow 53.38
Particulars MAR 2020 (Values in Cr)
Net Income -65.46
Cash from Operations 106.21
Cash from Investing -115.99
Cash from Financing -2.75
Net change in Cash -32.41
Free Cash Flow 186.51
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 76.74 13.41 100542.86 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 78.74 192.05 4.94 147.57 51.01 / 98.70
SHREE PACETRONIX LTD. 71.00 14.79 1.90 25.56 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.75 0.00 2.62 28.41 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 83.66 12.27 100542.86 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.25 0.00 -16.74 23.34 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5584.95 29.60 6.27 6109.94 3750.00 / 6400.00

HEALTHCARE GLOB. ENT. LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
562.45 2.88 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 558.50
  • 26 Days 547.20
  • 10 Days 560.40
  • 50 Days 532.40
  • 12 Days 559.20
  • 100 Days 510.30
  • 20 Days 552.20
  • 200 Days 474.30
551.05 PIVOT

First Support

539.45

First Resistance

558.30

Second Support

532.20

Second Resistance

569.90

Third Support

520.60

Third Resistance

577.15

RSI

50.14

ADX

28.67

MACD

11.99

Williams % R

-54.87

Commodity Channel Index (CCI)

-0.28

Date

2025-04-29

Week

112142.00

Same Day

67240.00

Month

157961.00

1 Year

0.57

3 Year

0.45

Over 1 Month

3.28%

down

Over 1 Year

50.27%

down

Over 3 Months

10.72%

down

Over 3 Years

24.71%

down

Over 6 Months

21.65%

down

Over 5 Years

48.69%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

HEALTHCARE GLOB. ENT. LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
13.85%
Promoter Holdings
71.21%
FII
2.44%
DII
12.47%
Promoter Shares(Pledge Percentage)
5.0%
Name Shares Category
Aceso Company Pte. Ltd. 8.4134078E7 (60.35%) Shareholding of Promoter and Promoter Group
Ajaikumar B S 1.4498715E7 (10.4%) Shareholding of Promoter and Promoter Group
Tata India Pharma & Healthcare Fund 4772362.0 (3.42%) Public Shareholding
Motilal Oswal S&p Bse Healthcare Etf 4335548.0 (3.11%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Els 3500000.0 (2.51%) Public Shareholding
Clarus Capital I 2535121.0 (1.82%) Public Shareholding
Asmitha Ajaikumar 327259.0 (0.23%) Shareholding of Promoter and Promoter Group
Aagnika Ajaikumar 327258.0 (0.23%) Shareholding of Promoter and Promoter Group
Anjali Ajaikumar Rossi 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Bhagya A Ajaikumar 1795.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

HEALTHCARE GLOB. ENT. LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

HEALTHCARE GLOB. ENT. LTD Share Price

Healthcare Global Enterprises Limited was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a Private Limited Company. The name of the Company was changed to HealthCare Global Enterprises Private Limited on November 14, 2005. Thereafter, it was converted into a Public Limited Company and the name of the Company was changed to Healthcare Global Enterprises Limited on July 5, 2006.

Presently, the Company is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. Under the 'HCG' brand, the Company operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB.

Under the 'Milann' brand, it operates fertility centres. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. The Milann network also operates on a model similar to our HCG network, wherein the various Milann fertility centres aim to provide medical services following established protocols with a focus on quality medical care across diagnosis and treatment. It provides comprehensive inpatient and outpatient treatments. Its key specialties include cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary and critical care.

Healthcare Global Enterprises provides clinical reference laboratory services in India under the Triesta brand with a specialisation in oncology, including molecular diagnostic services and genomic testing. It has Triesta central reference laboratory located in its centre of excellence in Bengaluru. The Triesta central reference laboratory is accredited by NABL in India, as well as by CAP for quality assurance of laboratory tests performed. Additionally, Triesta offers research and development services to pharmaceutical and biotechnology companies in the areas of clinical trial management and biomarker discovery and validation.

The company acquired 50.10% equity interest in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare.

HCG EKO Oncology LLP (HCG EKO LLP) HCG EKO LLP was incorporated on May 15, 2015, under the LLP Act as a limited liability partnership firm. HCG EKO LLP is authorised to primarily engage in the business of setting up hospitals at Kolkata with high end linear accelerators, oncology pharmacy and matters incidental and ancillary thereto.

HCG (Mauritius) Pvt. Ltd. (HCG Mauritius) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Mauritius is authorised to hold companies which are primarily engaged in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology.

HealthCare Global (Africa) Pvt. Ltd (HCG Africa) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Africa is authorised to engage in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology and hold companies which are engaged in the same business.

Healthcare Global Enterprises entered into a share purchase agreement dated November 23, 2015 with HCG TVH, its erstwhile subsidiary, and Anderson Diagnostics Private Limited. Pursuant to the terms of this agreement, Healthcare Global Enterprises has transferred its entire shareholding in HCG TVH aggregating 51% of the total paid up equity share capital of HCG TVH to Anderson Diagnostics Private Limited for an aggregate consideration of Rs.510,000. Accordingly, HCG TVH has ceased to be the subsidiary of the Company during the Financial Year.

During the financial year ended 31 March 2016, Healthcare Global Enterprises transferred its entire shareholding in HealthCare Global (Uganda) Private Limited ('HCG Uganda'), HealthCare Global (Kenya) Private Limited ('HCG Kenya') and HealthCare Global (Tanzania) Private Limited ('HCG Tanzania') to HealthCare Global (Africa) Pvt. Ltd. Accordingly, HCG Uganda, HCG Kenya and HCG Tanzania have become level two subsidiaries of the company.

During the year under review, Healthcare Global Enterprises introduced two major latest technologies at some of its centres viz. Robotic Surgery and Tomotherapy Treatment System. Robotic Surgery is an advanced form of minimally invasive or laparoscopic (small incision) surgery, where surgeons use a computer-controlled robot to assist them in certain surgical procedures. This facility was installed at Bangalore and Ahmedabad centres. The TomoTherapy treatment system uses a patented multi-leaf collimator (MLC) that divides the radiation beam into beamlets, all aimed at the tumor. More beam directions give physicians more control in how they plan treatments-and more assurance that dose will be confined to the tumor, reducing the risk of short- and long-term side effects. This facility was installed at Kalinga Rao Road centre, Bangalore.

During the financial year ended 31 March 2016, the company completed its Initial Public Offering (IPO) of 29,800,000 equity shares of Rs. 10 each, comprising of Fresh Issue of 11,600,000 equity shares and Offer For Sale of 18,200,000 equity shares at a premium of Rs. 208 per equity share. The total issue size was Rs. 6496.4 million. The IPO was open for subscription during the period from 16 to 18 March 2016. The shares got listed the National Stock Exchange of India Limited and BSE Limited on 30 March 2016. In April 2016, HCG launched its first cancer centre in Visakhapatnam, under its subsidiary company, HCG Pinnacle Oncology Private Limited. HCG Pinnacle Cancer Centre has a capacity of upto 88 beds and provides high quality and comprehensive cancer care services. In May 2016, the company launched its new advanced comprehensive cancer centre in Baroda, under its subsidiary, HCG Oncology LLP. The Centre has a bed capacity of 65 beds and is one of the most advanced in terms of technology in the HCG network.

HCG Pinnacle Oncology Private Limited, the wholly owned subsidiary of the Company was merged with the Company effective April 01, 2016. The Company launched the first dedicated comprehensive cancer hospital in Mumbai, in May 2017. In June 2017, HCG launched a comprehensive cancer centre in Nagpur, Maharashtra. The Cancer Care Centre in Kenya, Nairobi was acquired in July, 2017.

The Company in April, 2018 acquired 12% equity shares of International Stemcell Services Limited from its existing shareholders. HCG Manavata Cancer Centre, Nashik commenced its operations in May, 2018. The Company sold its entire shareholding in HCG Regency Oncology Healthcare Private Limited to Regency Hospital Limited (RHL) and HCG Regency ceased to be a subsidiary of the Company effective from March 29, 2018.

The Company commenced operations of the cancer center in Jaipur in 2018-19. The hospital in Bhavnagar commenced operations as comprehensive cancer center with launch of radiation services in the year 2019. The Nashik center commenced operations of phase 2 with a new building adjoining the original hospital, with advanced Tomotherapy Radiation technology, Bone Marrow transplant facilities and 92 beds. Also, the Company acquired 49.99% stake from its minority partner in Apex HCG Oncology Hospitals LLP, which operates the 1st private cancer center in Mumbai. The Company further commenced operations of 2 day care chemotherapy centers in Bengaluru. It commenced operations at 2 centers in Kolkata and South Mumbai.

Milann new center in Ahmedabad, launched in 2018, commenced operations in 2019 and Whitefield center was launched in 2019 in Bengaluru region. The hospital in Kolkata commenced launch of operations as comprehensive cancer center including Bone-Marrow Transplant (BMT) facilities in 2020. South Mumbai center was fully operationalised in FY 2020.

In FY 2022, the Company acquired an additional 60.9% in Suchirayu Healthcare Solutions, Hubli, Karnataka, from its existing share of 17.7%, to become a majority stake owner. It also acquired the oncology hospital labs and clinical trial business of Strand Life Sciences through a Business Transfer Agreement (BTA).

Parent organization Indian Private
NSE symbol HCG
Founded 1998
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Healthcare Global Enterprises Ltd?

Answer Field

The share price of Healthcare Global Enterprises Ltd for NSE is ₹ 562.45 and for BSE is ₹ 567.75.

What is the Market Cap of Healthcare Global Enterprises Ltd?

Answer Field

The market cap of Healthcare Global Enterprises Ltd for NSE is ₹ 78,34.34 Cr. and for BSE is ₹ 79,08.17 Cr. as of now.

What is the 52 Week High and Low of Healthcare Global Enterprises Ltd?

Answer Field

The 52 Week High and Low of Healthcare Global Enterprises Ltd for NSE is ₹ 601.95 and ₹ 330.65 and for BSE is ₹ 606.15 and ₹ 310.10.

How to Buy Healthcare Global Enterprises Ltd share?

Answer Field

You can trade in Healthcare Global Enterprises Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Healthcare Global Enterprises Ltd?

Answer Field

The 1 year returns on the stock has been 50.27%.

What is the Current Share Price of Healthcare Global Enterprises Ltd?

Answer Field

Healthcare Global Enterprises Ltd share price is for NSE ₹ 562.45 & for BSE ₹ 567.75 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Healthcare Global Enterprises Ltd Share?

Answer Field

The market cap of Healthcare Global Enterprises Ltd for NSE ₹ 78,34.34 & for BSE ₹ 79,08.17 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Healthcare Global Enterprises Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Healthcare Global Enterprises Ltd share is -803.24.

What is the PB ratio of Healthcare Global Enterprises Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Healthcare Global Enterprises Ltd share is 87.61.

How to Buy Healthcare Global Enterprises Ltd Share?

Answer Field

You can trade in Healthcare Global Enterprises Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Healthcare Global Enterprises Ltd Share on Bajaj Broking App?

Answer Field

To buy Healthcare Global Enterprises Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Healthcare Global Enterprises Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|